Medicine and Dentistry
B Cell
18%
Biocompatible Material
7%
Biological Marker
18%
Bleeding
8%
BRCA1
37%
Breast Cancer
6%
Cancer
27%
Cancer Registry
12%
Cancer Research
18%
CD8 Antigen
14%
Cell Expansion
7%
Cervical Cancer
73%
Cohort Analysis
40%
COVID-19
18%
Cumulative Incidence
7%
Cytoreductive Surgery
39%
Cytotechnology
18%
Debulking Surgery
20%
Disease
19%
Disease Free Survival
16%
Disease Specific Survival
12%
DNA Mismatch Repair
18%
Endometrial Cancer
43%
Estrogen Receptor
18%
Gynecological Oncology
76%
Hormone Therapy
18%
Immune Checkpoint Blockade
18%
Immune Response
7%
Krukenberg Tumor
18%
Lymph Duct
8%
Lymph Node Metastasis
18%
Neoadjuvant Chemotherapy
15%
Neoplasm
30%
Odds Ratio
20%
Open Surgery
8%
Ovarian Cancer
100%
Overall Survival
21%
Pembrolizumab
7%
Postoperative Complication
20%
Progesterone Receptor
15%
Radical Hysterectomy
39%
Receptor Expression
13%
Recurrent Disease
42%
Retrospective Cohort Study
20%
Salpingooophorectomy
37%
Serous Carcinoma
37%
Surgical Technique
8%
T Cell
13%
T Cell Subset
18%
Wart Virus
18%
Keyphrases
Abdominal Hysterectomy
18%
Adjuvant Chemotherapy
9%
Advanced Ovarian Cancer
18%
B Cells
18%
BRCA1, BRCA2
37%
Cancer Vaccine
18%
Clinical Auditing
18%
Clinical Quality Registry
18%
Confidence Interval
12%
Disease-free Survival
18%
Disease-specific Survival
12%
Dutch
37%
Early-stage Cervical Cancer
18%
Endometrial Cancer
18%
Fertility-sparing Surgery
18%
FIGO 2018
18%
First-in-human
18%
Germline Pathogenic Variant
37%
Gynecologic Oncology
37%
Hazard Ratio
9%
High-grade Cytology
9%
High-grade Serous Carcinoma
37%
High-grade Serous Ovarian Cancer (HGSOC)
18%
High-risk Human Papillomavirus (HR-HPV)
18%
Immune Checkpoint Blockade
18%
Immunization
18%
Interval Cytoreductive Surgery
18%
Laparoscopic Hysterectomy
18%
Median Time
9%
Mismatch Repair
18%
National Cohort Study
18%
Neoadjuvant
18%
Neoadjuvant Chemotherapy
9%
Netherlands
20%
Ovarian Cancer
21%
Overall Survival
21%
Pathological Response
11%
Patient Survival
18%
Phase I Clinical Trial
18%
Phase I Study
18%
Postoperative Outcomes
18%
Primary Cytoreductive Surgery
26%
Primary Debulking Surgery
24%
Quality Indicators
14%
Radiological Response
11%
Recurrence Rate
12%
Risk-reducing Salpingo-oophorectomy
37%
RNA Replicon
18%
Tumor
15%
Unknown Stage
12%
